{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020490","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.972625+00:00","generated_at":"2026-06-15T06:59:42.684177+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ginkgo Bioworks Q1 revenue $81M, down 52% YoY; Cell Engineering rev up 59%","bullets":["Q1 2023 total revenue $81M (down 52% YoY); Cell Engineering rev $34M (+59% YoY); Biosecurity rev $47M (52% gross margin).","Operating loss $(216)M (incl. $75M SBC); Adj. EBITDA $(100)M vs $(1)M prior year. Cash ~$1.2B.","Added 13 new Cell Programs (18% YoY growth); FY2023 outlook: at least 100 new programs, total rev ≥$275M.","Acquired StrideBio's AAV capsid engineering platform to advance gene therapy capabilities."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020490","json":"https://secwatch.observer/filing/0000950170-23-020490.json","markdown":"https://secwatch.observer/filing/0000950170-23-020490.md","text":"https://secwatch.observer/filing/0000950170-23-020490.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000095017023020490/0000950170-23-020490-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000095017023020490/dna-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:59:42.684177+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b08653c7469b3353b882a62264dc9e7a3ee3bec","claim":"Ginkgo Bioworks Holdings, Inc. reported first quarter ended March 31, 2023 results: revenue $81 million. Guidance reaffirmed.","evidence_excerpt":"First quarter 2023 Total revenue of $81 million, down from $168 million in the comparable prior year period, a decrease of 52% driven by the expected ramp down of K-12 testing in Ginkgo’s Biosecurity business unit","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1830214/000095017023020490/0000950170-23-020490-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$81 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}